Frazier Life Sciences Management, L.P. Immatics N.V. Transaction History

Frazier Life Sciences Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.18 - $7.42 $3.76 Million - $6.68 Million	-900,000 Reduced 41.9%	1,247,911 $5.63 Million
Q4 2024 Feb 14, 2025	BUY	$6.73 - $11.21 $5.34 Million - $8.89 Million	793,200 Added 58.55%	2,147,911 $15.3 Million
Q3 2024 Nov 15, 2024	BUY	$10.93 - $12.92 $2.21 Million - $2.61 Million	202,255 Added 17.55%	1,354,711 $15.5 Million
Q2 2024 Aug 15, 2024	BUY	$9.78 - $13.49 $11.3 Million - $15.5 Million	1,152,456 New	1,152,456 $13.4 Million

90.8M

201K

109K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $489M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.